Elevance Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 4, 2022, reports on a debt offering event that occurred on October 26, 2022. Elevance Health, Inc. (the "Company") closed a sale of senior notes pursuant to an Underwriting Agreement with BofA Securities, Inc. and Deutsche Bank Securities Inc.
Key Financial Metrics
The filing details a capital raise rather than operational performance metrics. Key figures include:
- Total Principal Amount Issued: $1.8 billion
- Net Proceeds Received: Approximately $1,780.2 million (after underwriting discounts and offering expenses)
- Debt Structure:
- $400.0 million of 5.350% Notes due 2025
- $650.0 million of 5.500% Notes due 2032
- $750.0 million of 6.100% Notes due 2052
- Interest Payment Schedule: Semi-annually in arrears on April 15 and October 15, commencing April 15, 2023.
Material Changes and Use of Proceeds
The Company intends to use the net proceeds for working capital and general corporate purposes. Specific uses include:
- Funding of acquisitions
- Repayment of short-term and long-term debt
- Repurchase of common stock pursuant to its share repurchase program
The Indenture governing the Notes does not prohibit or limit the incurrence of additional indebtedness or other liabilities by the Company or its subsidiaries.
Outlook, Risks, and Covenants
Redemption Rights: The Company may redeem the Notes prior to their respective "Par Call Dates" at a price equal to the greater of 100% of the principal amount or the present value of remaining payments plus a spread over the Treasury Rate. On or after the Par Call Dates, the Notes may be redeemed at 100% of the principal amount plus accrued interest.
Change of Control: If a change of control occurs and the Notes are downgraded below investment grade by Moody's, S&P, and Fitch, the Company must offer to purchase the Notes at 101% of the principal amount plus accrued interest.
Events of Default: Include failure to pay principal or interest, breach of Indenture terms for 90 days after notice, and bankruptcy or insolvency events.
Investor Verification Checklist
- Verify the exact net proceeds of $1,780.2 million against the gross principal of $1.8 billion to confirm underwriting costs.
- Review the Company's current debt maturity schedule to assess the impact of the new 2025, 2032, and 2052 maturities.
- Confirm the Company's current credit ratings with Moody's, S&P, and Fitch to evaluate the risk of a change-of-control repurchase trigger.
- Monitor future filings for the specific allocation of proceeds between debt repayment, acquisitions, and share repurchases.